Out-of-the-Box Marketing: Will It Work for Pharma?

This presentation put out-of-the-box marketing ideas such as Permission Marketing into the context of pharmaceutical promotions. Dr. Vanderveer -- the presenter -- posed important questions that pharmaceutical market researchers must ask themselves, especially in light of two looming pharmaceutical marketing crises: Decreasing ROI and Fewer Blockbuster Drugs.

The FTC-Lilly Consent Decree: What it Means for PHARMA Vendors and Partners

The 2002 settlement between ELi Lilly and the FTC regarding 'unauthorized disclosure of sensitive personal information collected from consumers' has an impact beyond Lilly. It also affects its agents who collect personally identifiable information from consumers in 'connection with the advertising, marketing, offering for sale, or sale of any pharmaceutical product…' Such agents could include interactive agencies that build and maintain Web sites, direct marketing agencies, fulfillment centers, market researchers, etc. If you are a pharmaceutical service provider, read this commentary to learn what you need to do to be compliant with privacy and security standards demanded by your pharma clients.

Pharma’s Confidence Crisis: A Call for a New Marketing Paradigm?

It is said by many that pharma is an industry in crisis. It faces weakening pipelines, spiraling costs and political adversity. It is plagued by pricing pressures on every front, increasingly competitive markets, patent challenges and public distrust. What is the root cause of its many other challenges? This article examines the crisis and discusses strategies for overcoming it with case examples.

Provider/Pharmaceutical Partnerships – Are They Possible Without Conflict of Interest?

What strategies should a pharmaceutical company follow to ensure a successful partnership with an academic CME provider? What's an appropriate measure for outcomes (ROI)? What % of income from academeic CME programs comes from pharma support?

Tailoring CRM Solutions to Your Business Strategy

Real World examples of CRM assessment and initial implementation, highlighting early best practices in CRM deployment was the theme of a panel discussion at CBI's 6th Original Forum on Customer Relationship Management (CRM) for the Pharmaceutical Industry, held in New York City, October 17-18, 2003. This article summarizes the panel discussion.

The Impact of eDetailing

The number of pharmaceutical sales representatives has increased sharply in recent years. More than 90,000 representatives compete for the attention of 650,000 practicing physicians, only 125,000 of whom are top-tier prescribers. Some people, maybe physicians most of all, hope that online detailing (eDetailing) will reduce the number of office visits from all these pharmaceutical sales representatives chasing after the same docs. This article reviews a presentation on this provocative topic made by David Hauben, Director of eBusiness at Aventis Pharmaceuticals at a recent industry conference.

Top Companies, Classes, and Products in the DTC Space

This article provides an overview of DTC spending YTD 2002 compared with YTD 2001. The sources the data are Verispan's Source Prescription Audit and other market research.

Developing Win-Win Key Opinion Leader Relationships

This article features results from research by Cutting Edge Information, a pharmaceutical business intelligence firm in Durham, North Carolina. Cutting Edge studied winning practices in thought leader management and has worked closely with more than a dozen KOL management executives from industry leaders, such as Pfizer, AstraZeneca and GlaxoSmithKline.

eMarketing at the Point of Care

Potent technologies like point-of-care electronic prescribing (e-prescribing) and related integrated drug reference tools are on the verge of becoming the most powerful marketing tools, since these technologies allow marketers to reach physicians when it matters most: when they are making the prescribing decision.

Guidelines for Off-label Communications

Off-label information distribution by pharmaceutical companies to physicians is legal and in common practice, though 'off-label confusion' might be the better term. This article reviews several court cases relating to false claims associated with off-label communications and suggests seven steps to safely for marketing a pharmaceutical product for an unapproved indication.
- Advertisement -